Evidence map›Paper›PMID 37249583›Full record

ArticleInnere Medizin (Heidelberg, Germany)2023

[Treatment alternatives for amyopathic MDA5-positive dermatomyositis].

Falk Schumacher, Maximilian Wollsching-Strobel, Doreen Kroppen, Sarah Bettina Schwarz, Johannes Strunk, Wolfram Windisch, Melanie Berger

Abstract readCase ReportsEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Innere Medizin (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Falk SchumacherKlinik für Rheumatologie, Krankenhaus Porz am Rhein gGmbH, Urbacher Weg 19, 51149, Köln, Deutschland. f.schumacher@khporz.de.
Maximilian Wollsching-StrobelLungenklinik Merheim, Kliniken der Stadt Köln GmbH, Köln, Deutschland.
Doreen KroppenLungenklinik Merheim, Kliniken der Stadt Köln GmbH, Köln, Deutschland.
Sarah Bettina SchwarzLungenklinik Merheim, Kliniken der Stadt Köln GmbH, Köln, Deutschland.
Johannes StrunkKlinik für Rheumatologie, Krankenhaus Porz am Rhein gGmbH, Urbacher Weg 19, 51149, Köln, Deutschland.
Wolfram WindischLungenklinik Merheim, Kliniken der Stadt Köln GmbH, Köln, Deutschland.
Melanie BergerLungenklinik Merheim, Kliniken der Stadt Köln GmbH, Köln, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of an atypical course of therapy in amyopathic MDA5-antibody-positive dermatomyositis with interstitial lung disease. Due to the poor prognosis, early therapy with cyclophosphamide followed by rituximab was carried out initially in addition to the administration of prednisolone. Due to therapy failure, treatment was switched to mycophenolate mofetil. This showed a surprisingly rapid positive course in terms of interstitial lung disease, skin manifestation, and general disease activity.

Indexed as

DermatomyositisLung Diseases, InterstitialAutoantibodiesHumansInterferon-Induced Helicase, IFIH1AutoantibodiesInterferon-Induced Helicase, IFIH1CyclophosphamideIdiopathic inflammatory myopathyInterdisciplinaryInterstitial lung diseaseMycophenolate mofetil

Identifiers

PMID37249583
PMCPMC10366251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.